Redeye summarizes the highlights of CLS’ business update event.
Redeye believes the offer from Matrix42 of EUR15 in cash per share is fair, considering the 91% prem...
Duell was able to grow its revenue 4.9% y/y during the seasonally slow Q1 as inorganic growth suppor...
Prostatype Genomics secured SEK 25m in growth capital in the latest right issue.
Q4 report due Thursday, 8 February at 07:00 CET '23e-'25e EBITA down 3-1%; 10% CAGR '22-'25e 12-10x ...
Q4e: sales SEK 32m, up 6.4% y-o-y, EBIT margin of 21.
Q4e: Cost cuts and price hikes lift earnings Minor estimate changes, EBITA +1% on FX Trading at 11x ...
Redeye comments on the slightly improved data, which are becoming mature, from the latest readout of...
Redeye leaves its forecasts for Q4 and 2024 roughly unchanged and comments on the change in Autodesk...
Redeye updates its estimates for the Q4 2023 report (due 1 February 2024) with lower sales estimates...
Redeye is favorable to the expansion of the distribution network for Switzerland and Lichtenstein by...
Kommande fas IIb-studie Guard meddelade på måndagen att bolaget, efter återkoppling från FDA, planer...
Redeye updates its estimates before TECO’s Q4 report, where we expect that deals have been pushed to...
Q4'23 results due 2 February 23e EBITDA cut 1.4% and down 11.
Redeye endorses CLS’ market approval for its TRANBERG portfolio in Singapore.
Aptahem genomför mellan den 15-29 januari år 2024 en företrädesemission om 34,6 MSEK.
Redeye is surprised that I-Tech's CEO, Philip Chaabane has decided to step down from his position fo...
Redeye comments on Thomson Reuters' increased public offer of SEK50 per share, which the independent...
Redeye expects improved numbers in Q4 relative to soft Q2-Q3 due to seasonality and improved underly...
Redeye comments on Arise’s production figure for the fourth quarter, which was released on Friday ev...
.jpg)
